Himanshu Savardekar

The Ohio State University Wexner Medical Center — United States

Immunology and Microbiology · Life Sciences

7h-index215citations101works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune cells in cancer(46), Cancer Immunotherapy and Biomarkers(29), Chemokine receptors and signaling(26), Cytokine Signaling Pathways and Interactions(20), Lung Cancer Research Studies(20)

Publications101 total

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
2025Open Access
Supplementary Tables 1-5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
2025Open Access
Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
2025Open Access
Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
2025Open Access
Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
2025Open Access
Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
2025Open Access
BRD4 inhibition leads to MDSC apoptosis and enhances checkpoint blockade therapy
Journal of Clinical Investigation·2025· 3 citedOpen Access
Figure 3 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2025Open Access
Figure 6 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2025Open Access
Supplementary Table S2 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2025Open Access
Figure 5 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2025Open Access
Supplementary Figure S6 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2025Open Access
Supplementary Table S3 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2025Open Access
Figure 1 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2025Open Access
Supplementary Figure S7 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2025Open Access
Supplementary Figure S4 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2025Open Access
Supplementary Table S4 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2025Open Access
Data from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2025Open Access
Figure 4 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2025Open Access
Supplementary Figure S3 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2025Open Access
page 1 of 6Next →

Frequent Co-authors

William E. Carson(46), Emily Schwarz(37), Gabriella Lapurga(32), Robert Wesolowski(32), Sara Zelinskas(27), Kari Kendra(24), Dionisia Quiroga(22), Andrew Stiff(21), Brooke Benner(20), Jianying Li(17), Jami Shaffer(17), Bradley W. Blaser(17), Gang Xin(17), Carter Allen(16), Richard C. Wu(16), Alexander Abreo(16), Matthew Old(16), Dongjun Chung(16), Hyeongseon Jeon(15), Lianbo Yu(13)